

Characteristics of SARS-CoV-2 positive and complicated COVID-19 patient cohorts in Israel: A comparative analysis

Authors. Chen Yanover^{1,*†}, Barak Mizrahi^{1,*}, Nir Kalkstein¹, Karni Marcus¹, Pinchas Akiva¹, Yael Barer², Varda Shalev², Gabriel Chodick^{2,3}

Affiliation. ¹KI Research Institute, Kfar Malal, Israel; ²Maccabi Institute for Research and Innovation, Tel Aviv, Israel; ³Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

* Equally contributing authors

† Corresponding author: Chen Yanover, KI Research Institute, 11 Hazayit st, Kfar Malal, Israel. Email: chen@kinstitute.org.il

Abstract

Reliably identifying patients at increased risk for COVID-19 complications could guide clinical decisions, public health policies, and preparedness efforts. The most globally accepted definitions of at-risk patients rely, primarily, on epidemiological characterization of hospitalized COVID-19 patients. However, such characterization overlooks, and fails to correct for, the prevalence of existing conditions in the wider SARS-CoV-2 positive population. Here, we use the complete medical records of 4,353 Israeli SARS-CoV-2 positive individuals, of whom 173 experienced moderate or severe symptoms of COVID-19, to identify the conditions that increase the risk of disease complications, in various age and sex strata. Our analysis suggests that cardiovascular and kidney diseases, obesity, and hypertension are significant risk factors for COVID-19 complications, as previously reported. Interestingly, it also indicates that depression (e.g., odds ratio, OR, for males 65 years or older: 2.94, 95% confidence intervals [1.55, 5.58]; P-value = 0.014) as well cognitive and neurological disorder (e.g., OR for individuals \geq 65 year old: 2.65 [1.69, 4.17]; P-value < 0.001) are significant risk factors; and that smoking and background of respiratory diseases do not significantly increase the risk of complications. Adjusting existing risk definitions following these observations may improve their accuracy and impact the global pandemic containment efforts.

Introduction

As of May 7th, 2020, close to four million people worldwide contracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and more than 265,000 people died of corona virus disease 2019 (COVID-19) complications. This pandemic poses grave challenges to patients, healthcare providers, and policy makers. Many of these challenges may be better addressed with timely stratification of patients to risk groups, based on their past and current medical characteristics. For example, reliably identifying patients at increased (or decreased) risk could guide clinical decisions (e.g., hospitalization vs home care), public health policies (e.g., risk-based quarantine), and preparedness efforts (e.g., expected medical equipment required).

Dozens of studies providing epidemiological characterization of severe COVID-19 patients have been published in the last few months. For example, meta-analysis of twenty Chinese studies [1] suggested that elderly males with a high body mass index (BMI), high breathing rate and a combination of underlying comorbidities (e.g., hypertension, diabetes, cardiovascular disease, and chronic obstructive pulmonary disease) are at a high risk of developing severe complications; and a more recent study characterized patients hospitalized with COVID-19 in the New York City area and compared, side-by-side, the clinical measures for patients discharged alive, died, or remained in hospital [2].

Consequently, a few algorithms for identifying patients at risk for COVID-19 (severe) complications have been proposed. The Centers for Disease Control and Prevention (CDC) identified individuals 65 years and older, living at nursing home or long-term care facility, or suffering from underlying medical conditions, particularly if not well controlled, as being at high risk for severe illness from COVID-19 [3]. Similarly, the European Centre for Disease Prevention and Control (ECDC) lists age above 70 years and some underlying conditions as risk factors for critical illness [4]. The United Kingdom National Health Service (NHS) included solid organ transplant recipients, patient with specific cancers or severe respiratory conditions, pregnant women with significant heart disease, and those with increased risk of infection (e.g., due to immunosuppression therapies) in the highest clinical COVID-19 risk group [5]. On April 2020 approximately 1.3 million people in this group were asked to “shield” by staying at home for a period of at least 12 weeks. In addition, patients over 70 years and those suffering from some underlying health conditions (e.g., chronic respiratory diseases, BMI \geq 40, and pregnant women) were considered in a wider vulnerable group (also referred to as the “flu group”). Finally, a more quantitative risk model has been adopted by the Israeli Ministry of Health (MoH), assigning a point for each underlying condition from a predefined list, then considering age group and point count to identify high risk patients.

The vast majority of published reports characterized hospitalized (typically, severe) COVID-19 patients and only a handful analyzed broader (though small) cohorts of symptomatic individuals (e.g., [6]). These studies excluded, by design, patients who did not require hospitalization or asymptomatic ones. As such, it is unclear to what extent the prevalence of comorbidities in the studied population differs from that of same age (and sex) SARS-CoV-2 positive patients; and, accordingly, whether these comorbidities are significant risk factors for severe COVID-19 or merely a reflection of comorbidity prevalence in the wider population. Unlike these studies, we compare here the prevalence of existing conditions in SARS-CoV-2 positive and complicated COVID-19 patients and identify those associated with COVID-19 complications in various age and sex strata. Our analysis highlights stratum-specific risk factors and may allow better identification of patients at risk, in different subpopulations.

Methods

Maccabi COVID-19 data

Maccabi Health Services (MHS) is a nationwide health plan (payer-provider), representing a quarter of the Israeli population. The MHS database contains longitudinal data on a stable population of over 2.3 million people since 1993 (with annual attrition rate lower than 1%). Data are automatically collected and include comprehensive laboratory data from a single central lab, full pharmacy prescription and purchase data, and extensive demographic information on each patient.

Studied cohorts

SARS-CoV-2 polymerase chain reaction testing in Israel uses both nasopharyngeal and saliva samples. Individuals with positive testing result (until April 22, 2020) are included in the *SARS-CoV-2 positive cohort*. Positive patients whose disease status, as updated by Israeli hospitals, deteriorated to moderate or severe (at any point in time), admitted to the intensive care unit, or died constitute the *complicated COVID-19 cohort*; the remaining SARS-CoV-2 positive patients (including asymptomatic, mild COVID-19 patients or those with unknown status) constitute the *non-complicated COVID-19 cohort*.

Existing conditions

Beside age and sex, we considered a set of existing conditions, comprising those included in the CDC, NHS, and Israeli MoH at-risk definitions, as well as a set of conditions showing significant association with flu and flu-like complications.

To identify each individual's existing conditions, we used, where available, registries created and maintained by MHS. These registries are based on validated inclusion and exclusion criteria (considering coded diagnoses, treatment, labs, and imaging, as applicable). The registries are continuously and retrospectively (since 1998) updated based on each patient's central medical record. Patients may be excluded from a registry when deemed misclassified by their primary physician. Linkage across registries and with other sources of information is performed via a unique national identification number. MHS registries used are: Cardiovascular diseases (including ischemic heart disease, congestive heart failure, peripheral vascular disease, cerebrovascular disease, and other cardiovascular diseases) [7], diabetes [8,9], hypertension [10], osteoporosis [11], chronic kidney disease [12], cognitive disorders, mental illness [13], cancer, immunosuppression, weight disorders (obesity, overweight and underweight), smoking, and nursing home. For other conditions, we relied on previously grouped lists of diagnosis codes (Read codes or International Classification of Diseases, ICD, codes, ninth revision) [14–16]: Deficiency anemia, Fluid and electrolyte disorders, chronic obstructive pulmonary disease (COPD), chronic pulmonary disease, neurological disorders, end stage renal disease, rheumatoid arthritis, paralysis, hip fracture, lymphoma, aspiration pneumonia, pleural effusion, respiratory failure, and alcohol consumption.

Statistical analysis

We extracted the prevalence of the studied conditions in the non-complicated and complicated COVID-19 cohorts and measured the association between each condition and disease complications by computing the corresponding odds ratio and its estimated statistical significance (using Fisher's exact test). We conducted the analysis separately in three age groups: 18-50 years, 50-65 years, and 65 years and older; as well as four (age, sex) strata: male or female, younger or older than 65 years. Finally, to account for multiple testing, we controlled for the false discovery rate using Benjamini and Hochberg's method [17]. All analyses were performed using version 4.0.0 of the R programming language (R Project for Statistical Computing; R Foundation).

Results

Maccabi Health Services (MHS) cohort included 4,353 SARS-CoV-2 positive individuals, of whom 173 deteriorated to moderate or severe condition, admitted to the intensive care unit, or died (complicated COVID-19 cohort; see Methods). Overall, patients in the complicated COVID-19 cohort are older, suffer from more comorbidities, and are more predominantly male (Table 1). Moreover, the prevalence of COVID-19 complications increases with age, and more steeply for men than for women (Figure 1); and the risk of COVID-19 complications in men under 70 years is significantly higher than in women (and Table 2).




Figure 1. Age and complicated COVID-19. Prevalence of complicated COVID-19 (moderate or severe condition, y-axis) in different age groups (x-axis), shown separately for male (blue) and female (orange).

Comparing the prevalence of existing conditions in three age groups between the complicated and non-complicated COVID-19 cohorts, reveals multiple risk factors, including obesity for patient 18-50 years (OR: 11.09, 95% confidence intervals, CI: [4.15, 32.67]; P-value < 10^{-4}), Chronic kidney disease for patients 50-65 years (4.06 [1.89, 8.38]; P-value = 0.005); and neurological disorders (2.65 [1.69, 4.17]; P-value < 0.001) for patients 65 years or older (for a complete list, see Table 3 and Supplementary File 1).

Stratifying over age (below and above 65 years) and sex (Table 4 and Supplementary File 1), kidney diseases appear as a risk factor in all strata (e.g., OR 3.45 [1.57, 8.06]; P-value = 0.015 in women 65 years or more). Additional risk factors include hypertension in males under 65 years (4.56 [2.35, 8.55]; P-value < 0.001); neurological disorders in females 65 years or older (3.55 [1.68, 7.74]; P-value = 0.008); cognitive impairment (4.18 [1.81, 9.72]; P-value = 0.009) and depression (2.94 [1.55, 5.58]; P-value = 0.014) in males 65 years or older.

Intriguingly, respiratory diseases and smoking, which contribute to common at-risk definitions (including those by the CDC [3] and the British NHS [5]), while typically more prevalent in complicated COVID-19 patients, are not identified as significant risk factors (e.g., chronic obstructive pulmonary disease in patients 65 years or more: OR 1.36 [0.75, 2.4]; P-value = 0.634); and see Supplementary File 1.

Table 1. Characteristics of the SARS-CoV-2 positive, complicated, and non-complicated COVID-19 patient cohorts.

	SARS-Cov-2 positive	Complicated COVID-19	Non-complicated COVID-19
Demographic information			
N	4353	173	4180
Age median [inter quantile range, IQR]	35 [22-54]	70 [58-80]	34 [22-52]
<18y	647 (15%)	0 (0%)	647 (15.6%)
18-50y	2354 (54.5%)	21 (12.1%)	2333 (56.3%)
50-60y	609 (14.1%)	29 (16.8%)	580 (14%)
60-70y	376 (8.7%)	35 (20.2%)	341 (8.2%)
70-80y	232 (5.4%)	42 (24.3%)	190 (4.6%)
80y≤	135 (3.1%)	46 (26.6%)	89 (2.1%)
Female	1939 (44.5%)	50 (28.9%)	1889 (45.2%)
Comorbidities			
<i>Chronic respiratory diseases</i>			
Chronic obstructive pulmonary disease	481 (11%)	39 (22.5%)	442 (10.6%)
Other chronic pulmonary disease	310 (7.1%)	24 (13.9%)	286 (6.8%)
Pleural effusion	153 (3.5%)	10 (5.8%)	143 (3.4%)
Pleural effusion	41 (0.9%)	4 (2.3%)	37 (0.9%)
<i>Cardiovascular diseases</i>			
Ischemic heart disease	310 (7.1%)	57 (32.9%)	253 (6.1%)
Ischemic heart disease	132 (3%)	27 (15.6%)	105 (2.5%)
Congestive heart failure	30 (0.7%)	11 (6.4%)	19 (0.5%)
Cerebrovascular disease	57 (1.3%)	15 (8.7%)	42 (1%)
Peripheral vascular disease	23 (0.5%)	7 (4%)	16 (0.4%)
Other cardiovascular diseases	199 (4.6%)	41 (23.7%)	158 (3.8%)
Hypertension	627 (14.4%)	102 (59%)	525 (12.6%)
Immunosuppression	164 (3.8%)	31 (17.9%)	133 (3.2%)
Cancer	205 (4.7%)	33 (19.1%)	172 (4.1%)
Deficiency anemia	423 (9.7%)	18 (10.4%)	405 (9.7%)
<i>Liver and kidney diseases</i>			
Liver disease	404 (9.3%)	28 (16.2%)	376 (9%)
Chronic kidney disease	384 (8.8%)	86 (49.7%)	298 (7.1%)
End stage renal disease	85 (2%)	26 (15%)	59 (1.4%)
<i>Fluid and electrolyte disorders</i>			
Fluid and electrolyte disorders	394 (9.1%)	37 (21.4%)	357 (8.5%)
<i>Metabolic diseases</i>			
Diabetes	362 (8.3%)	58 (33.5%)	304 (7.3%)
Obesity (BMI≥30)	874 (20.1%)	73 (42.2%)	801 (19.2%)
<i>Neurological and cognitive disorders</i>			
Neurological disorders	294 (6.8%)	57 (32.9%)	237 (5.7%)
Paralysis	53 (1.2%)	12 (6.9%)	41 (1%)
Depression	578 (13.3%)	53 (30.6%)	525 (12.6%)
Cognitive impairment	87 (2%)	28 (16.2%)	59 (1.4%)
<i>Other</i>			
Hospitalization	931 (21.4%)	92 (53.2%)	839 (20.1%)
Smoking	643 (14.8%)	41 (23.7%)	602 (14.4%)
Current smoker	514 (11.8%)	30 (17.3%)	484 (11.6%)
Past smoker	129 (3%)	11 (6.4%)	118 (2.8%)
Nursing home	67 (1.5%)	23 (13.3%)	44 (1.1%)
Home care	44 (1%)	17 (9.8%)	27 (0.6%)

Table 2. Association of male sex and COVID-19 complications across age groups.

Age group	Patient counts ^a	OR ^b	P-value ^c
18-50y	(18/1300,3/1033)	4.77 [1.39, 25.32]	0.013
50-60y	(25/314,4/266)	5.28 [1.79, 21.15]	0.003
60-70y	(29/202,6/139)	3.32 [1.31, 10.03]	0.013
70-80y	(27/108,15/82)	1.36 [0.65, 2.95]	0.473
80y≤	(24/32,22/57)	1.93 [0.89, 4.26]	0.145

^a Number of males in the complicated/non-complicated COVID-19 cohorts, followed by the corresponding numbers in females

^b Odds ratios (ORs) and 95% confidence intervals (in brackets). ORs greater than 1 suggest an increased risk for COVID-19 complications in males

^c P-values adjusted for multiple testing using Benjamini and Hochberg method [17]. Rows are sorted ascendingly by P-value.

Table 3. Most statistically significant conditions associated with increased risk of COVID-19 complications in age stratified patient groups.

Condition	Age group	Patient counts ^a	OR ^b	P-value ^b
Obesity	18-50y	(14/356,7/1977)	11.09 [4.15, 32.67]	2.36E-05
Depression	18-50y	(7/229,14/2104)	4.59 [1.55, 12.3]	0.032
Hypertension	18-50y	(4/72,17/2261)	7.37 [1.76, 23.41]	0.035
Liver disease	18-50y	(5/125,16/2208)	5.51 [1.55, 16.07]	0.037
Chronic kidney disease	50-65y	(14/87,27/683)	4.06 [1.89, 8.38]	0.005
End stage renal disease	50-65y	(5/8,36/762)	13.11 [3.21, 48.19]	0.006
Neurological disorders	65y≤	(54/113,57/317)	2.65 [1.69, 4.17]	6.24E-04
Chronic kidney disease	65y≤	(70/174,41/256)	2.51 [1.6, 3.97]	0.001
Other cardiovascular diseases	65y≤	(36/70,75/360)	2.46 [1.49, 4.05]	0.006
Cognitive impairment	65y≤	(28/52,83/378)	2.45 [1.4, 4.22]	0.015
Home care	65y≤	(16/22,95/408)	3.12 [1.47, 6.48]	0.022
Hypertension	65y≤	(82/249,29/181)	2.05 [1.27, 3.4]	0.027
Cardiovascular diseases	65y≤	(50/129,61/301)	1.91 [1.22, 2.99]	0.032
Nursing home	65y≤	(20/35,91/395)	2.48 [1.29, 4.65]	0.036

^a Number of patients with the condition (cases) in the complicated/non-complicated COVID-19 cohorts, followed by the corresponding numbers in patients without the studied condition (controls)

^b Odds ratios (ORs) and P-values as defined in Table 2. ORs greater than 1 suggest an increased risk for COVID-19 complications in patients with the noted condition

Table 4. Most statistically significant conditions associated with increased risk of COVID-19 complications in age and sex stratified patient groups. See Table 3 for column information.

Condition	Age, sex group	Patient counts	OR	P-value
End stage renal disease	age<65; Female	(2/5,7/1370)	75.7 [6.23, 570.01]	0.014
Immunosuppression	age<65; Female	(3/46,6/1329)	14.35 [2.25, 69.89]	0.032
Chronic kidney disease	age<65; Female	(3/58,6/1317)	11.3 [1.78, 54.41]	0.041
Chronic kidney disease	age<65; Male	(13/66,40/1662)	8.16 [3.82, 16.5]	2.36E-05
Hypertension	age<65; Male	(17/162,36/1566)	4.56 [2.35, 8.55]	5.34E-04
Obesity	age<65; Male	(25/359,28/1369)	3.4 [1.88, 6.14]	0.001
Hospitalization	age<65; Male	(21/285,32/1443)	3.32 [1.79, 6.04]	0.004
End stage renal disease	age<65; Male	(3/7,50/1721)	14.67 [2.38, 66.53]	0.029
Diabetes	age<65; Male	(9/105,44/1623)	3.16 [1.32, 6.79]	0.040
Neurological disorders	65≤age; Female	(26/66,15/136)	3.55 [1.68, 7.74]	0.008
Chronic kidney disease	65≤age; Female	(30/89,11/113)	3.45 [1.57, 8.06]	0.015
Home care	65≤age; Female	(10/16,31/186)	3.72 [1.38, 9.69]	0.036
Other cardiovascular diseases	65≤age; Female	(15/33,26/169)	2.94 [1.3, 6.51]	0.038
Cardiovascular diseases	65≤age; Female	(19/48,22/154)	2.76 [1.29, 5.85]	0.045
Cognitive impairment	65≤age; Male	(16/15,54/213)	4.18 [1.81, 9.72]	0.009
Depression	65≤age; Male	(26/38,44/190)	2.94 [1.55, 5.58]	0.014
Neurological disorders	65≤age; Male	(28/47,42/181)	2.56 [1.38, 4.73]	0.022
End stage renal disease	65≤age; Male	(19/26,51/202)	2.88 [1.39, 5.9]	0.027
Chronic kidney disease	65≤age; Male	(40/85,30/143)	2.24 [1.26, 4.02]	0.034
Fluid and electrolyte disorders	65≤age; Male	(17/22,53/206)	2.99 [1.39, 6.38]	0.034

Discussion

We compared the prevalence of dozens of existing conditions in Israeli SARS-CoV-19 positive and complicated COVID-19 patient cohorts, to highlight those conditions associated with high risk of complications. Our approach differs from most (if not all) previous studies, which focused on hospitalized or symptomatic patients and had no (or limited) access to out-of-hospital (likely, asymptomatic and mildly sick) patients.

Many conditions highlighted by our analysis have been previously reported [1,2,6] and are part of commonly used at-risk definitions [3,5], including hypertension, obesity, kidney and cardiovascular diseases. We do, however, identify a few additional risk factors, notably depression in patients 18-50 years old and males 65 years or more; and cognitive and neurological disorders in patients 65 years or older. These additions may be, in part, associated with different age distribution in the 65+ years group (median 76y, IQR [70-83.5y] versus 72y [68-78y] in the complicated and non-complicated COVID-19 cohorts, respectively) and rely on small sample size (only seven 18-50y patients with depression in the complicated COVID-19 cohort; Table 3); nonetheless, they may deserve more consideration in future studies. Our analysis also points out to reduced importance of respiratory diseases and smoking. Both conditions appear as factors in most at-risk definitions [3,5]: Chronic obstructive pulmonary disease has been associated with severe COVID-19 in multiple (though not all [6]) studies [18], while the role of smoking has been somewhat controversial [18,19]. The discrepancies between our analysis and previous reports likely stem from the different cohorts analyzed: SARS-CoV-2 positive individuals, ranging from asymptomatic to severe COVID-19 versus hospitalized COVID-19 patients, respectively. Other study-related attributes, for example country-specific characteristics, may also contribute to the varying significance of the studied risk factors.

In parallel to the COVID-19 epidemiological characterization efforts, researchers have also attempted to use retrospective observational data to derive risk models for severe COVID-19 patients [20]. Such models require ample data of COVID-19 patients for both model training and performance assessment. As, currently, such data are scarce, some models compromised on using data for other diseases with, supposedly, similar clinical trajectory and complications. For example, DeCapprio et al [19] trained models on US Medicare claims data to predict inpatient visits with a primary diagnosis of either pneumonia, influenza, acute bronchitis, or other specified upper respiratory infections as proxy for COVID-19 complications. However, as previously reported (e.g., in [22]), and in agreement with our analysis, severe COVID-19 patient characteristics differ considerably from other diseases', thus undermining the generalizability of such models to COVID-19.

Our study has several limitations. First and foremost, the number of complicated COVID-19 patients in MHS data is below 200, limiting the statistical power of our analysis. Second, healthcare policies and, in particular, testing criteria, may systematically bias the composition of SARS-CoV-2 positive cohort. Third, asymptomatic and mild COVID-19 patients (currently in the non-complicated cohort) may deteriorate and eventually be part of the complicated cohort, potentially modifying the results of the analysis. Fourth, our analysis is univariate in nature, testing the association of individual conditions with COVID-19 complications; as such, it is unable to uncover more complex relations, e.g., interdependencies between conditions and COVID-19 complications. Finally, we focused on data from Israel; characteristics in other geographies may differ [22]. We attempted to mitigate some of these limitations by age and sex stratification and robust estimations of statistical significance. We also note that, at the current point in time, many of these shortcomings are shared by all published COVID-19 research work.

Notwithstanding these limitations, our work adopts a novel vantage point to the problem of identifying patients at increased risk for COVID-19 complications. Importantly, as SARS-CoV-2 containment efforts focus on patients at risk for severe complications (for example, shielding vulnerable population in the UK [5]), changes in the list of considered conditions may have huge effect on a large number of individuals, thus calling for continuous fine-tuning of the corresponding definitions.

Supplementary Information

Supplementary File 1. Odds ratio analysis.

Ethical approval

The study was approved by Maccabi Health Services' institutional review board.

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form, with the following declarations made: PA reports personal fees and other from Medial Research, outside the submitted work.

Acknowledgement

We thank Guy Amit and Irena Girshovitz, KI Research Institute, for insightful discussions and comments.

Author Contributions

Conceptualization: NK; **Data Curation:** BM, KM, YB; **Investigation and methodology:** CY, BM, NK; **Project Administration:** PA, VS; **Writing – original draft preparation:** CY; **Writing – review and editing:** CY, BM, KM, PA, YB, GC.

References

1. Xu L, Yaqian M, Chen G. Risk factors for severe corona virus disease 2019 (COVID-19) patients : a systematic review and meta analysis | medRxiv. [cited 21 Apr 2020]. Available: <https://www.medrxiv.org/content/10.1101/2020.03.30.20047415v1>
2. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020 [cited 28 Apr 2020]. doi:10.1001/jama.2020.6775
3. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19). 11 Feb 2020 [cited 21 Apr 2020]. Available: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html>
4. European Centre for Disease Prevention and Control. Rapid risk assessment: Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – eighth update. In: European Centre for Disease Prevention and Control [Internet]. 8 Apr 2020 [cited 21 Apr 2020]. Available: <https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-coronavirus-disease-2019-covid-19-pandemic-eighth-update>
5. United Kingdom National Health Service. Guidance and updates for GPs: Highest clinical risk patients. [cited 27 Apr 2020]. Available: <https://www.england.nhs.uk/coronavirus/publication/guidance-and-updates-for-gps-at-risk-patients/>
6. Pre-Existing Characteristics Associated with Covid-19 Illness Severity | medRxiv. [cited 7 May 2020]. Available: <https://www.medrxiv.org/content/10.1101/2020.04.29.20084533v1>
7. Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. *Int J Cardiol*. 2011;152: 345–349. doi:10.1016/j.ijcard.2010.08.002
8. Sella T, Shoshan A, Goren I, Shalev V, Blumenfeld O, Laron Z, et al. A retrospective study of the incidence of diagnosed Type 1 diabetes among children and adolescents in a large health organization in Israel, 2000-2008. *Diabet Med J Br Diabet Assoc*. 2011;28: 48–53. doi:10.1111/j.1464-5491.2010.03174.x
9. Chodick G, Heymann AD, Shalev V, Kookia E. The epidemiology of diabetes in a large Israeli HMO. *Eur J Epidemiol*. 2002;18: 1143–1146. doi:10.1023/B:EJEP.0000006635.36802.c8
10. Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E. Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. *Hypertens Dallas Tex* 1979. 2014;64: 501–507. doi:10.1161/HYPERTENSIONAHA.114.03718
11. Goldshtein I, Nguyen AM, dePapp AE, Ish-Shalom S, Chandler JM, Chodick G, et al. Epidemiology and correlates of osteoporotic fractures among type 2 diabetic patients. *Arch Osteoporos*. 2018;13: 15. doi:10.1007/s11657-018-0432-x
12. Yu J, Goldshtein I, Shalev V, Chodick G, Ish-Shalom S, Sharon O, et al. Renal impairment among postmenopausal women with osteoporosis from a large health plan in Israel. *Arch Osteoporos*. 2015;10: 210. doi:10.1007/s11657-015-0210-y

13. Kodesh A, Goldshtein I, Gelkopf M, Goren I, Chodick G, Shalev V. Epidemiology and comorbidity of severe mental illnesses in the community: findings from a computerized mental health registry in a large Israeli health organization. *Soc Psychiatry Psychiatr Epidemiol.* 2012;47: 1775–1782. doi:10.1007/s00127-012-0478-9
14. Metcalfe D, Masters J, Delmestri A, Judge A, Perry D, Zogg C, et al. Coding algorithms for defining Charlson and Elixhauser co-morbidities in Read-coded databases. *BMC Med Res Methodol.* 2019;19: 115. doi:10.1186/s12874-019-0753-5
15. Kuan V, Denaxas S, Gonzalez-Izquierdo A, Direk K, Bhatti O, Husain S, et al. A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. *Lancet Digit Health.* 2019;1: e63–e77. doi:10.1016/S2589-7500(19)30012-3
16. Clinical Classifications Software (CCS) 2015. Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP); Available: <https://www.hcup-us.ahrq.gov/toolssoftware/ccs/CCSUsersGuide.pdf>
17. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B Methodol.* 1995;57: 289–300. doi:10.2307/2346101
18. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis. *J Med Virol.* n/a. doi:10.1002/jmv.25889
19. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). *Eur J Intern Med.* 2020;75: 107–108. doi:10.1016/j.ejim.2020.03.014
20. Wynants L, Van Calster B, Bonten MMJ, Collins GS, Debray TPA, De Vos M, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. *BMJ.* 2020; m1328. doi:10.1136/bmj.m1328
21. DeCaprio D, Gartner J, Burgess T, Kothari S, Sayed S, McCall CJ. Building a COVID-19 Vulnerability Index. *ArXiv200307347 Cs Stat.* 2020 [cited 21 Apr 2020]. Available: <http://arxiv.org/abs/2003.07347>
22. Burn E, You SC, Sena A, Kostka K, Abedtash H, Abrahao MTF, et al. An international characterisation of patients hospitalised with COVID-19 and a comparison with those previously hospitalised with influenza. *medRxiv.* 2020; 2020.04.22.20074336. doi:10.1101/2020.04.22.20074336